ABOUT 
SPECIALTY CARE
The Benefits of New Diabetes Medications: GLP Drugs and SGLT2 Inhibitors
Updated: 09/23/24
Download Patient SGLT2i HandoutDownload Patient GLP-1 RA HandoutThese one-page guide will answer your patient's most common questions when starting an SGL2i medication like Jardiance, Farxiga, Invokana, or Steglatro and GLP-1 RA medications like Ozempic, Rybelsus, Trulicity, Victoza, Bydureon BCise, or Byetta.
Developed by MCT2D Co-Director and clinical pharmacist Heidi Diez, PharmD and MKIC Directors Michael Heung, MD, Julie Wright, MD, MPH, and Rajiv Saran, MD, MBBS, MS, with Lauren Oshman, MD, MPH.
Note: This handout should not be used as a substitute for medical advice from your health care team. It is your responsibility to review information provided by your pharmacy and consult with your doctor or health care team member prescribing these medications with any questions about your medication.
Patients: Please leave feedback about this tool (counts towards PO-Level VBR requirement)Tags: For Patients, Point-of-care, Created By MCT2D, Handout
Subscribe to the MCT2D Newsletter
Once per month we deliver news, updates, events, and more directly to you!
ccteam@mct2d.org
Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.